Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: A phase I trial
    Journal Article

    Gangat, N.; Marinaccio, C.; Swords, R.; Watts, J. M.; Gurbuxani, S.; Rademaker, A.; Fought, A. J.; Frankfurt, O.; Altman, J. K.; Wen, Q. J.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Thrombosis in the Philadelphia chromosome-negative myeloproliferative neoplasms
    Journal Article

    Sankar, K.; Stein, B. L.; Rampal, R. K.
    Cancer Treatment and Research (2019)

    Fulltext@MSK | Save
  • Challenges and approaches to implementing master/basket trials in oncology
    Review

    Burd, A.; Schilsky, R. L.; Byrd, J. C.; Levine, R. L.; Papadimitrakopoulou, V. A.; Herbst, R. S.; Redman, M. W.; Druker, B. J.; Gandara, D. R.
    Blood Advances (2019)

    Fulltext@MSK | Save
  • Oral idasanutlin in patients with polycythemia vera
    Journal Article

    Mascarenhas, J.; Lu, M.; Kosiorek, H.; Virtgaym, E.; Xia, L.; Sandy, L.; Mesa, R.; Petersen, B.; Farnoud, N.; Najfeld, V.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Journal Article

    Sauter, C. S.; Senechal, B.; RivieĢ€re, I.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Singh, A. N.; Szenes, V. Z.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Targeted therapies for myeloproliferative neoplasms
    Review

    Li, B.; Rampal, R. K.; Xiao, Z.
    Biomarker Research (2019)

    Fulltext@MSK | Save
  • Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
    Review

    Branford, S.; Kim, D. D. H.; Apperley, J. F.; Eide, C. A.; Mustjoki, S.; Ong, S. T.; Nteliopoulos, G.; Ernst, T.; Chuah, C.; Gambacorti-Passerini, C.; more...
    Leukemia (2019)

    Fulltext@MSK | Save
  • Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia in the United States
    Meeting Abstract

    Huntington, S. F.; Strunz-McKendry, T.; Masaquel, A. S.; Shapouri, S.; Sail, K.; Durno, N.; Mato, A.
    Value in Health (2019)

    Fulltext@MSK | Save
  • Genetic targeting of ERK1/ERK2 kinases impairs the fitness of the myeloproliferative neoplasm clone
    Meeting Abstract

    Stivala, S.; Brkic, S.; Dirnhofer, S.; Passweg, J. R.; Tsakiris, D. A.; Neel, B. G.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2019)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on targetable MAPK activation and is reversible
    Meeting Abstract

    Szybinski, J.; Codilupi, T.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Radimerski, T.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2019)

    Fulltext@MSK | Save